Circulating subsets and CD4⁺CD25⁺ regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy

References

• Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005; 352 13: 1343–1356.
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Periph Nerv Sys. 2006; 11 1: 30–46.
   PubMed Web of Science ®Google Scholar
• Mäurer M, Gold R. Animal models of immune-mediated neuropathies. Curr Opin Neurol. 2002; 15 5: 617–622.
   PubMed Web of Science ®Google Scholar
• Allen D, Giannopoulos K, Gray I, Gregson N, Makowska A, Pritchard J, Hughes RAC. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy. J Periph Nerv Sys. 2005; 10 2: 174–180.
   PubMed Web of Science ®Google Scholar
• Csurhes PA, Sullivan AA, Green K, Pender MP, McCombe PA. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain–Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psych. 2005; 76 10: 1431–1439.
   PubMed Web of Science ®Google Scholar
• Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psych. 2007; 78 4: 419–422.
   PubMed Web of Science ®Google Scholar
• Sanvito L, Makowska A, Mahdi-Rogers M, Hadden RD, Peakman M, Gregson N, Nemni R, Hughes RA. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2009; 80 3: 333–338.
   PubMed Web of Science ®Google Scholar
• Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006; 103 15: 5941–5946.
   PubMed Web of Science ®Google Scholar
• De Jager PL, Rossin E, Pyne S, Tamayo P, Ottoboni L, Viglietta V, Weiner M, Soler D, Izmailova E, Faron-Yowe L, O'Brien C, Freeman S, Granados S, Parker A, Roubenoff R, Mesirov JP, Khoury SJ, Hafler DA, Weiner HL. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain. 2008; 131 7: 1701–1711.
   PubMedGoogle Scholar
• Hostmann A, Jacobi AM, Mei H, Hiepe F, Dorner T. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus. 2008; 17 12: 1064–1069.
   PubMed Web of Science ®Google Scholar
• Saraste M, Irjala H, Airas L. Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci. 2007; 28 3: 121–126.
   PubMed Web of Science ®Google Scholar
• Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005; 105 11: 4390–4398.
   PubMed Web of Science ®Google Scholar
• Seidi OA, Semra YK, Sharief MK. Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis. J Neuroimmunol. 2002; 133 1: 205–210.
   PubMed Web of Science ®Google Scholar
• Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dorner T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000; 165 10: 5970–5979.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401 6754: 708–712.
   PubMed Web of Science ®Google Scholar
• Haegele K, Stueckle C, Malin J, Sindern E. Increase of CD8+T-effector memory cells in peripheral blood of patients with relapsing–remitting multiple sclerosis compared to healthy controls. J Neuroimmunol. 2007; 183 1–2: 168–174.
   PubMed Web of Science ®Google Scholar
• Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CGM. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int. 2006; 70 5: 938–947.
   PubMed Web of Science ®Google Scholar
• Sen Y, Chunsong H, Baojun H, Linjie Z, Qun L, San J, Qiuping Z, Junyan L, Zhang X, Jinquan T. Aberration of CCR7+ CD8+ memory T cells from patients with systemic lupus erythematosus: an inducer of T helper type 2 bias of CD4+ T cells. Immunology. 2004; 112 2: 274–289.
   PubMed Web of Science ®Google Scholar
• Giunti D, Borsellino G, Benelli R, Marchese M, Capello E, Valle MT, Pedemonte E, Noonan D, Albini A, Bernardi G, Mancardi GL, Battistini L, Uccelli A. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leuk Biol. 2003; 73 5: 584–590.
   PubMed Web of Science ®Google Scholar
• Trebst C, Brunhorn K, Lindner M, Windhagen A, Stangel M. Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins. Eur J Neurol. 2006; 13 12: 1359–1363.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008; 9 5: 503–510.
   PubMed Web of Science ®Google Scholar
• Créange A, Gregson NA, Hughes RAC. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte Fc-gamma RII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol. 2003; 135 1–2: 91–95.
   PubMed Web of Science ®Google Scholar
• Mata S, Corzani S, Biagiotti R, Piacentini S, Siracusa G, Giudizi MG, Mastio MD, Borsini W, Taiuti R, Vultaggio A, Sorbi S, Maggi E. Influence of impaired T- and B-cell compartments on efficacy of IVIg in dysimmune neuropathies. Eur J Neurol. 2007; 14 10: 1147–1153.
   PubMed Web of Science ®Google Scholar
• Dahle C, Vrethem M, Ernerudh J. T lymphocyte subset abnormalities in peripheral blood from patients with the Guillain–Barré syndrome. J Neuroimmunol. 1994; 53 2: 219–225.
   PubMed Web of Science ®Google Scholar
• Harness J, Mc Combe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain–Barré syndrome patients compared to controls. J Clin Neurosci. 2008; 15 9: 1031–1035.
   PubMed Web of Science ®Google Scholar
• Sindern E, Oreja-Guevara C, Raulf-Heimsoth M, Baur X, Malin JP. A longitudinal study of circulating lymphocyte subsets in the peripheral blood during the acute stage of Guillain–Barré syndrome. J Neurol Sci. 1997; 151 1: 29–34.
   PubMed Web of Science ®Google Scholar
• Yoshii F, Shinohara Y. Lymphocyte subset proportions in Guillain–Barré syndrome patients treated with plasmapheresis. Eur Neurol. 2000; 44 3: 162–167.
   PubMed Web of Science ®Google Scholar
• Chi LJ, Wang HB, Zhang Y, Wang WZ. Abnormality of circulating CD4+CD25+ regulatory T cell in patients with Guillain–Barré syndrome. J Neuroimmunol. 2007; 192 1–2: 206–214.
   PubMed Web of Science ®Google Scholar
• Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Periph Nerv Sys. 2008; 13 1: 54–63.
   PubMed Web of Science ®Google Scholar
• Pritchard J, Makowska A, Gregson NA, Hayday AC, Hughes RAC. Reduced circulating CD4+CD25+ cell populations in Guillain–Barré syndrome. J Neuroimmunol. 2007; 183 1–2: 232–238.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol. 2004; 22 1: 531–562.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299 5609: 1057–1061.
   PubMed Web of Science ®Google Scholar
• Hartigan-O'Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods. 2007; 319 1–2: 41–52.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev. 2006; 212:203–216.
   PubMed Web of Science ®Google Scholar
• Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. 2007; 178 4: 2579–2588.
   PubMed Web of Science ®Google Scholar
• Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199 7: 971–979.
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Bouche P, Cornblath DR, Evers E, Hadden RDM, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, Van den Bergh P, van Doorn PA, van Schaik IN. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2006; 13 4: 326–332.
   PubMed Web of Science ®Google Scholar
• Makowska A, Pritchard J, Sanvito L, Gregson N, Peakman M, Hayday A, Hughes R. Immune responses to myelin proteins in Guillain–Barré syndrome. J Neurol Neurosurg Psych. 2008; 79 6: 664–671.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001; 167 3: 1245–1253.
   PubMed Web of Science ®Google Scholar
• Rizzuto N, Morbin M, Cavallaro T, Ferrari S, Fallahi M, Rizzuto GS. Focal lesions area feature of chronic inflammatory demyelinating polyneuropathy (CIDP). Acta Neuropathol. 1998; 96 6: 603–609.
   PubMed Web of Science ®Google Scholar
• Mizutani K, Oka N, Kaji R, Matsui M, Asanuma K, Kubori T, Kojima Y, Kanda M, Kawanishi T, Tomimoto H, Akiguchi I, Shibasaki H. CD16+CD57− Natural killer cells in multifocal motor neuropathy. Eur Neurol. 2005; 53 2: 64–67.
   PubMed Web of Science ®Google Scholar
• Yoshii F, Shihohara Y. Natural killer cells in patients with Guillain–Barré syndrome. J Neurol Sci. 1998; 157 2: 175–178.
   PubMed Web of Science ®Google Scholar
• Vrethem M, Dahle C, Ekerfeldt C, Nilsson J, Ekstedt B, Ernerudh J. Abnormalities in T-lymphocyte populations in blood from patients with demyelinating polyneuropathy associated with monoclonal gammopathy. J Neurol Sci. 1994; 122 2: 171–178.
   PubMed Web of Science ®Google Scholar
• Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. Differential expression of NK T cell Valpha24-JalphaQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol. 2000; 164 8: 4375–4381.
   PubMed Web of Science ®Google Scholar
• Segal BM. The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol. 2007; 191 1–2: 2–7.
   PubMed Web of Science ®Google Scholar
• Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TIM. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes. 2005; 54 1: 92–99.
   PubMed Web of Science ®Google Scholar
• Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'hooghe MB, Dubois B, Raus J, Stinissen P. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and Foxp3 expression. J Neurosci Res. 2006; 83 8: 1432–1446.
   PubMed Web of Science ®Google Scholar
• Crispin JC, Martinez A, Cocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003; 21 3: 273–276.
   PubMed Web of Science ®Google Scholar
• De Luca G, Lugaresi A, Iarlori C, Marzoli F, Uncini A, Gambi D. Interferon- beta normalizes suppressor cell function in dysimmune neuropathies. J Neuroimmunol. 1998; 82 1: 1–4.
   PubMed Web of Science ®Google Scholar
• De Luca G, Lugaresi A, Iarlori C, Marzoli F, Di Iorio A, Gambi D, Uncini A. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1999; 95 1–2: 190–194.
   PubMed Web of Science ®Google Scholar
• Susuki K, Rasband MN. Molecular mechanisms of node of Ranvier formation. Curr Opin Cell Biol. 2008; 20 6: 616–623.
   PubMed Web of Science ®Google Scholar
• Graham RC, Hughes RA. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry. 2006; 77 8: 973–976.
   PubMed Web of Science ®Google Scholar